Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Women's Life Medical Science, Gangnam Severance Hospital, Seoul, Republic of Korea.
Neurobiol Dis. 2021 Jul;155:105374. doi: 10.1016/j.nbd.2021.105374. Epub 2021 Apr 30.
Huntington's disease (HD) starts its pathology long before clinical manifestation, however, there is no therapy to cure it completely and only a few studies have been reported for delaying the progression of HD. Recently, it has been shown that heterochronic parabiosis can modulate the neurodegenerative diseases. Despite the importance of the transportation process of positive factors during heterochronic parabiosis, there were limited understandings because the transportation process is nanoscale, which makes it difficult to identify the messenger unit. We demonstrated that heterochronic parabiosis could modulate HD in R6/2 mice model, and identified the messenger unit for transferring positive factors in the young blood serum.
R6/2 mice were surgically connected with young wild-type mice (n = 13), old wild-type mice (n = 8), or R6/2 mice (n = 6) to examine the effect of heterochronic parabiosis. Parabionts composed of 5- to 6-week-old transgenic and wild-type mice were observed for 6 weeks in a single cage. The in vitro cellular model of HD cells were treated by the blood serum of the young or old mice, and by the exosomes isolated from thereof. The in vitro cellular model of HD were developed by differentiating neural stem cells cultured from SVZ of the brain.
After the heterochronic parabiosis, the weight loss and survival of HD mice was improved. Also, mutant Huntingtin aggregation (EM48 p < 0.005), improvement of mitochondria dysfunction (PGC-1a p < 0.05, p-CREB/CREB p < 0.005), cell death (p53 p < 0.05, Bax p < 0.05, Cleaved-caspase3 p < 0.05), and cognition (DCX p < 0.5) showed a near complete restoration. In addition, treating in vitro cellular model of HD by the exosomes from young blood serum improved mutant Huntingtin aggregation (EM48 p < 0.05), mitochondria biogenesis (p-CREB/CREB p < 0.005), cell death (p53 p < 0.05, Bax p < 0.005, Cleaved-caspase3 p < 0.05, Bcl-2 p < 0.05), and cell proliferation (WST-1 p < 0.005).
We found that the overall pathology of HD could be improved by the shared blood circulation through heterochronic parabiosis, furthermore, we demonstrated that the exosomes could be messengers for transferring positive factors, showing the potential of exosomes from young blood for the amelioration of HD.
亨廷顿病(HD)在出现临床症状之前很早就开始了其病理学过程,然而,目前还没有完全治愈它的疗法,只有少数研究报告了延迟 HD 进展的方法。最近,已经表明异时性并体可以调节神经退行性疾病。尽管在异时性并体中传递正因子的过程很重要,但由于该过程是纳米级的,因此很难识别信使单元,因此对其了解有限。我们证明了异时性并体可以调节 R6/2 小鼠模型中的 HD,并鉴定了在年轻血清中传递正因子的信使单元。
通过手术将 R6/2 小鼠与年轻野生型小鼠(n=13)、老年野生型小鼠(n=8)或 R6/2 小鼠(n=6)相连,以检查异时性并体的作用。由 5-6 周龄转基因和野生型小鼠组成的并体在单个笼子中观察 6 周。用年轻或老年小鼠的血清以及从中分离出的外泌体处理体外 HD 细胞模型。体外 HD 细胞模型是通过分化大脑 SVZ 培养的神经干细胞建立的。
异时性并体后,HD 小鼠的体重减轻和存活率得到改善。此外,突变亨廷顿蛋白聚集(EM48p<0.005)、线粒体功能障碍改善(PGC-1ap<0.05,p-CREB/CREBp<0.005)、细胞死亡(p53p<0.05,Baxp<0.05,Cleaved-caspase3p<0.05)和认知(DCXp<0.5)均接近完全恢复。此外,用来自年轻血清的外泌体处理体外 HD 细胞模型可改善突变亨廷顿蛋白聚集(EM48p<0.05)、线粒体生物发生(p-CREB/CREBp<0.005)、细胞死亡(p53p<0.05,Baxp<0.005,Cleaved-caspase3p<0.05,Bcl-2p<0.05)和细胞增殖(WST-1p<0.005)。
我们发现,通过异时性并体共享血液循环可以改善 HD 的整体病理学,此外,我们证明了外泌体可以作为传递正因子的信使,表明年轻血液中的外泌体具有改善 HD 的潜力。